1. Wotring, V. Chemical potency and degradation products of medications stored over 550 earth days at the international space station. AAPS J. 18, 210–216 (2016).
2. Daniels, V. & Bayuse, T. Risk of ineffective or toxic medications during long-duration exploration spaceflight. Oral Presentation, NASA Human Systems Risk Board (2018).
3. Dose tracker application for monitoring medication usage, symptoms, and adverse effects during missions.
https://www.nasa.gov/mission_pages/station/research/experiments/1933.html
.
4. Antonsen, E. et al. The risk of adverse health outcomes and decrements in performance due to in-flight medical conditions. Tech. Rep. NASA/JSC-20170004604, National Aeronautics and Space Administration (2017).
5. Putcha, L., Berens, K., Marshburn, T., Ortega, H. & Billica, R. Pharmaceutical use by U.S. astronauts on space shuttle missions. Aviat. Space Environ. Med. 70, 705–708 (1999).